Cargando…

Combination of CALR and PDIA3 is a potential prognostic biomarker for non-small cell lung cancer

Proteomic-based approaches for biomarker discovery are promising strategies used in cancer research. In this study, we performed quantitative proteomic analysis on 16 paired samples of non-small cell lung cancer (NSCLC) and adjacent non-tumor lung tissues using label-free quantitative proteomics and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Ke, Li, Hao, Chen, Ruo, Zhang, Yang, Sun, Xiu-Xuan, Huang, Wan, Bian, Huijie, Chen, Zhi-Nan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722536/ https://www.ncbi.nlm.nih.gov/pubmed/29228584 http://dx.doi.org/10.18632/oncotarget.18547

Ejemplares similares

CALR-TLR4 Complex Inhibits Non-Small Cell Lung Cancer Progression by Regulating the Migration and Maturation of Dendritic Cells
por: Chen, Ruo, et al.
Publicado: (2021)

Evidence for Recombinant GRP78, CALR, PDIA3 and GPI as Mediators of Genetic Instability in Human CD34+ Cells
por: Fabarius, Alice, et al.
Publicado: (2022)

Expression and Prognostic Significance of PDIA3 in Cervical Cancer
por: Zhang, Jing, et al.
Publicado: (2022)

Identification of differentially expressed genes in non-small cell lung cancer
por: Wang, Ke, et al.
Publicado: (2019)

PDIA4 Correlates with Poor Prognosis and is a Potential Biomarker in Glioma
por: Li, Haoyu, et al.
Publicado: (2021)

A Comparative Analysis of Punicalagin Interaction with PDIA1 and PDIA3 by Biochemical and Computational Approaches
por: Paglia, Giuliano, et al.
Publicado: (2021)

Aromatic sulphonamides of aziridine-2-carboxylic acid derivatives as novel PDIA1 and PDIA3 inhibitors
por: Zelencova-Gopejenko, D., et al.
Publicado: (2023)

Mice with Calr mutations homologous to human CALR mutations only exhibit mild thrombocytosis
por: Shide, Kotaro, et al.
Publicado: (2019)

PDIA2 variant associated with vitiligo
por: Li, Fucheng, et al.
Publicado: (2023)

Allelic imbalance in CALR somatic mutagenesis
por: Harutyunyan, A S, et al.
Publicado: (2015)

Pan-Cancer Analysis of the Immunological Role of PDIA5: A Potential Target for Immunotherapy
por: Chen, Yu, et al.
Publicado: (2022)

Bioinformatics analysis for the role of CALR in human cancers
por: Li, Yijun, et al.
Publicado: (2021)

ERp57/PDIA3: new insight
por: Chichiarelli, Silvia, et al.
Publicado: (2022)

Inhibition of PDIA3 in club cells attenuates osteopontin production and lung fibrosis
por: Kumar, Amit, et al.
Publicado: (2022)

PDIA6 modulates apoptosis and autophagy of non-small cell lung cancer cells via the MAP4K1/JNK signaling pathway
por: Bai, Yuxin, et al.
Publicado: (2019)

CALR mutation characterization in myeloproliferative neoplasms
por: Bilbao-Sieyro, Cristina, et al.
Publicado: (2016)

CALR Mutation Underlying Silent Stroke
por: Faryal, Rehman, et al.
Publicado: (2021)

Pan-Cancer Analysis of PDIA3: Identifying It as a Potential Biomarker for Tumor Prognosis and Immunotherapy
por: Zhang, Jing, et al.
Publicado: (2022)

Impaired Bone Formation in Pdia3 Deficient Mice
por: Wang, Yun, et al.
Publicado: (2014)

The role of PDIA3 in myogenesis during muscle regeneration
por: Wang, Chao, et al.
Publicado: (2020)

Thrombopoietin receptor is required for the oncogenic function of CALR mutants
por: Nivarthi, H, et al.
Publicado: (2016)

PDIA5 is Correlated With Immune Infiltration and Predicts Poor Prognosis in Gliomas
por: Zhang, Hao, et al.
Publicado: (2021)

The Contemporary Approach to CALR-Positive Myeloproliferative Neoplasms
por: Belčič Mikič, Tanja, et al.
Publicado: (2021)

CALR mutations in myeloproliferative neoplasms: An unfolding story
por: Langabeer, Stephen E.
Publicado: (2020)

Protective Role for the Disulfide Isomerase PDIA3 in Methamphetamine Neurotoxicity
por: Pendyala, Gurudutt, et al.
Publicado: (2012)

Comparative Analysis of the Interaction between Different Flavonoids and PDIA3
por: Giamogante, Flavia, et al.
Publicado: (2016)

Essential thrombocythemia with CALR mutation and recurrent stroke: two case reports and literature review
por: Chen, Rong, et al.
Publicado: (2022)

PDIA6 contributes to aerobic glycolysis and cancer progression in oral squamous cell carcinoma
por: Mao, Ling, et al.
Publicado: (2021)

PDIA3 correlates with clinical malignant features and immune signature in human gliomas
por: Zhang, Hao, et al.
Publicado: (2020)

Expression of CALR mutants causes mpl-dependent thrombocytosis in zebrafish
por: Lim, K-H, et al.
Publicado: (2016)

Pdia4 regulates β‐cell pathogenesis in diabetes: molecular mechanism and targeted therapy
por: Kuo, Tien‐Fen, et al.
Publicado: (2021)

Calreticulin (CALR)-induced activation of NF-ĸB signaling pathway boosts lung cancer cell proliferation
por: Gao, Fangfang, et al.
Publicado: (2022)

Chimeric antigen receptor T cells targeting CD147 for non-small cell lung cancer therapy
por: Chen, Xiao-Hong, et al.
Publicado: (2021)

Essential cell-extrinsic requirement for PDIA6 in lymphoid and myeloid development
por: Choi, Jin Huk, et al.
Publicado: (2020)

Therapeutic Targeting of Protein Disulfide Isomerase PDIA1 in Multiple Myeloma
por: Hasipek, Metis, et al.
Publicado: (2021)

PDIA3 Knockdown Exacerbates Free Fatty Acid-Induced Hepatocyte Steatosis and Apoptosis
por: Zhang, Xue-qun, et al.
Publicado: (2015)

Acute Lymphoblastic Leukemia Arising in CALR Mutated Essential Thrombocythemia
por: Langabeer, Stephen E., et al.
Publicado: (2016)

Detecting CALR Mutations in Splanchnic Vein Thrombosis: Who and How?
por: Langabeer, Stephen E.
Publicado: (2018)

Splenic mass in a case of CALR‐mutated essential thrombocythemia
por: Imashuku, Shinsaku, et al.
Publicado: (2018)

Sequential evaluation of CALR mutant burden in patients with myeloproliferative neoplasms
por: Cavalloni, Chiara, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ftp1cgp0qio5em5dvnuulp6nmh